Search Results
You are looking at 1 - 2 of 2 items for
- Author: Yue-Fang Liu x
- Refine by access: All content x
Department of Biology, Shantou University, Shantou, China
Search for other papers by Jie Liu in
Google Scholar
PubMed
Search for other papers by Fei Gao in
Google Scholar
PubMed
Search for other papers by Yue-Fang Liu in
Google Scholar
PubMed
Search for other papers by Hai-Ting Dou in
Google Scholar
PubMed
Search for other papers by Jia-Qi Yan in
Google Scholar
PubMed
Search for other papers by Zong-Min Fan in
Google Scholar
PubMed
Search for other papers by Zeng-Ming Yang in
Google Scholar
PubMed
Embryo implantation and decidualization are key steps for successful reproduction. Although numerous factors have been identified to be involved in embryo implantation and decidualization, the mechanisms underlying these processes are still unclear. Based on our preliminary data, Prss56, a trypsin-like serine protease, is strongly expressed at implantation site in mouse uterus. However, the expression, regulation and function of Prss56 during early pregnancy are still unknown. In mouse uterus, Prss56 is strongly expressed in the subluminal stromal cells at implantation site on day 5 of pregnancy compared to inter-implantation site. Under delayed implantation, Prss56 expression is undetected. After delayed implantation is activated by estrogen, Prss56 is obviously induced at implantation site. Under artificial decidualization, Prss56 signal is seen at the primary decidual zone at the initial stage of artificial decidualization. When stromal cells are induced for in vitro decidualization, Prss56 expression is significantly elevated. Dtprp expression under in vitro decidualization is suppressed by Prss56 siRNA. In cultured stromal cells, HB-EGF markedly stimulates Prss56 expression through EGFR/ERK pathway. Based on promoter analysis, we also showed that Egr2 is involved in Prss56 regulation by HB-EGF. Collectively, Prss56 expression at implantation site is modulated by HB-EGF/EGFR/ERK signaling pathway and involved in mouse decidualization.
Search for other papers by Can Liu in
Google Scholar
PubMed
Search for other papers by Mian Zhang in
Google Scholar
PubMed
Search for other papers by Meng-yue Hu in
Google Scholar
PubMed
Search for other papers by Hai-fang Guo in
Google Scholar
PubMed
Search for other papers by Jia Li in
Google Scholar
PubMed
Search for other papers by Yun-li Yu in
Google Scholar
PubMed
Search for other papers by Shi Jin in
Google Scholar
PubMed
Search for other papers by Xin-ting Wang in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Xiao-dong Liu in
Google Scholar
PubMed
Panax ginseng is one of the most popular herbal remedies. Ginsenosides, major bioactive constituents in P. ginseng, have shown good antidiabetic action, but the precise mechanism was not fully understood. Glucagon-like peptide-1 (GLP1) is considered to be an important incretin that can regulate glucose homeostasis in the gastrointestinal tract after meals. The aim of this study was to investigate whether ginseng total saponins (GTS) exerts its antidiabetic effects via modulating GLP1 release. Ginsenoside Rb1 (Rb1), the most abundant constituent in GTS, was selected to further explore the underlying mechanisms in cultured NCI-H716 cells. Diabetic rats were developed by a combination of high-fat diet and low-dose streptozotocin injection. The diabetic rats orally received GTS (150 or 300 mg/kg) daily for 4 weeks. It was found that GTS treatment significantly ameliorated hyperglycemia and dyslipidemia, accompanied by a significant increase in glucose-induced GLP1 secretion and upregulation of proglucagon gene expression. Data from NCI-H716 cells showed that both GTS and Rb1 promoted GLP1 secretion. It was observed that Rb1 increased the ratio of intracellular ATP to ADP concentration and intracellular Ca2 + concentration. The metabolic inhibitor azide (3 mM), the KATP channel opener diazoxide (340 μM), and the Ca2 + channel blocker nifedipine (20 μM) significantly reversed Rb1-mediated GLP1 secretion. All these results drew a conclusion that ginsenosides stimulated GLP1 secretion both in vivo and in vitro. The antidiabetic effects of ginsenosides may be a result of enhanced GLP1 secretion.